[1] |
Singh P, Kumar V, Gupta SK, et al. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review[J]. Med Oncol, 2021, 38:10. doi: 10.1007/s12032-021-01462-5.
|
[2] |
于游游,李彬,闫婷,等. miR-221对慢性粒细胞白血病K562细胞增殖和凋亡的影响及其作用机制[J]. 中国肿瘤生物治疗杂志,2019,26:1311-1317.
|
[3] |
Lan X, Zhao C, Chen X, et al. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms[J]. J Hematol Oncol, 2016, 9:129. doi: 10.1186/s13045-016-0359-x.
|
[4] |
Litwińska Z, Machaliński B. MiRNAs in chronic myeloid leukemia: small molecules, essential function[J]. Leuk Lymphoma, 2017, 58:1297-1305.
|
[5] |
Zhao M, Liu Q, Liu W, et al. MicroRNA-140 suppresses helicobacter pylori-positive gastric cancer growth by enhancing the antitumor immune response[J]. Mol Med Rep, 2019, 20:2484-2492.
|
[6] |
陈翔,黄路,张中卒,等. miR-140在骨肉瘤组织中表达降低及其过表达可促进骨肉瘤U2细胞的凋亡[J]. 基础医学与临床,2016,36:439-444.
|
[7] |
Jiang W, Li T, Wang J, et al. miR-140-3p suppresses cell growth and induces apoptosis in colorectal cancer by target-ing PD-L1[J]. Onco Targets Ther, 2019, 12:10275-10285.
|
[8] |
Baccarani M, Rosti G, Soverini S. Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type[J]. Leukemia, 2019, 33:2358-2364.
|
[9] |
Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies[J]. Cancer Cell, 2020, 37:530-542.
|
[10] |
Lin Z, Pan J, Chen L, et al. miR-140 resensitizes cisplatin-resistant NSCLC cells to cisplatin treatment through the SIRT1/ROS/JNK pathway[J]. Onco Targets Ther, 2020,13:8149-8160.
|
[11] |
Carter BZ, Mak PY, Mu H, et al. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells[J]. Sci Transl Med, 2016, 8:355ra117. doi: 10.1126/scitranslmed.aag1180.
|
[12] |
Goff DJ, Court Recart A, Sadarangani A, et al. A pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition[J]. Cell Stem Cell, 2013, 12: 316-328.
|
[13] |
Kuroda J, Kimura S, Andreeff M, et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms[J]. Br J Haematol, 2008,140:181-190.
|